Steven Cohen Clearside Biomedical, Inc. Call Options Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.98 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.31 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$2.03 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$838,0430.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$782,1330.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $63.2M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...